AGTC-501 is named as an intervention in 2 current clinical trials in our USA, UK, Canada and Australia registers. None are recruiting at the moment. The most common phase is Phase 2/3. The lead sponsor is Beacon Therapeutics. The most-studied condition is X-Linked Retinitis Pigmentosa.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study Comparing Two Doses of AGTC-501 in Male Participants With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (DAWN)
NCT06275620 · ClinicalTrials.gov ↗ · X-Linked Retinitis Pigmentosa
|
Phase 2 | By invitation | Beacon Therapeutics | USA |
|
A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP
NCT04850118 · ClinicalTrials.gov ↗ · X-Linked Retinitis Pigmentosa
|
Phase 2/3 | Active, closed | Beacon Therapeutics | UK, USA, Canada, Australia |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Beacon Therapeutics | 2 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 2 | 0 |
| Clinical trials in UK | 1 | 0 |
| Clinical trials in Canada | 1 | 0 |
| Clinical trials in Australia | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our USA, UK, Canada and Australia registers name AGTC-501 (also registered as RAAV2tYF-GRK1-hRPGRco) as a drug or biological intervention, as of the registry sync on 28 September 2026. Completed and withdrawn studies are not counted.
Not at the moment. None of the 2 trials in our registers is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.
The lead sponsor is Beacon Therapeutics. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how AGTC-501 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how AGTC-501 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists AGTC-501 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 28 Sep 2026.